MRPL13 act as a novel therapeutic target and could promote cell proliferation in non-small cell lung cancer
Cancer Management and Research — Jing CQ, Fu R, Wang C, et al. | July 13, 2021
Researchers sought to determine the role of mitochondrial ribosomal protein L13 (MRPL13), a member of the mitochondrial ribosomal protein family, in non-small cell lung cancer (NSCLC). They conducted all analyses in R software 4.0, SPSS version 23, and GraphPad Prism 8, and used A549 and H1299 lung cancer cell lines for phenotypic experiments. A correlation of high level of MRPL13 with poor T classification as well as overall survival was found. A high expression of MRPL13 in NSCLC tissue and cell lines was revealed by in vitro experiments. Inhibition of the proliferation of lung cancer A549 and H1299 cell lines was brought about by MRPL13 knockdown, and this was further validated via in vivo experiment. Overall, findings indicate that MRPL13 may not only promote the proliferation of NSCLC cells but also has utility as an independent tumor marker as well as an emerging treatment target.
Your browser is currently blocking ads. We depend on ad sponsorships in order to keep this site free to the healthcare provider community. Help us keep this site free by turning off your ad blocker.
Turn Off Ad Blocker
We have detected that you are currently blocking ads. We kindly ask that you enable ads when visiting our site. We depend on ad sponsorships in order to keep this site free to the healthcare provider community.